Haiko J Bloemendal (Haiko Bloemendal)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Radical Prostatectomy

Arterial Hypertension

Top Venues

Cancer chemotherapy and pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research

Journal of market access & health policy

This page only lists publications with an associated author ORCID identifier.

Publications

Marise R Heerma van Voss, Jessica C L Notohardjo, Joyce M van Dodewaard-de Jong, Haiko J Bloemendal, Rob Ter Heine
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer chemotherapy and pharmacology (2024)
Marise R Heerma van Voss, Jessica C L Notohardjo, Joyce M van Dodewaard-de Jong, Haiko J Bloemendal, Rob Ter Heine
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer chemotherapy and pharmacology (2024)
J Maxime van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts, Louisa R Hoes, Hanneke van der Wijngaart, Vincent van den Noort, Alwin D R Huitema, Filip Yves Francine De Vos, Katrien Grünberg, Haiko J Bloemendal, Henk M W Verheul, Emile E Voest, André B P van Kuilenburg
Maximizing treatment opportunities: assessing protocol waivers' impact on safety and outcome in the Drug Rediscovery Protocol. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
J Maxime van Berge Henegouwen, Laurien J Zeverijn, Birgit S Geurts, Louisa R Hoes, Hanneke van der Wijngaart, Vincent van den Noort, Alwin D R Huitema, Filip Yves Francine De Vos, Katrien Grünberg, Haiko J Bloemendal, Henk M W Verheul, Emile E Voest, André B P van Kuilenburg
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (17) (2024)
Marise R Heerma van Voss, Jessica C L Notohardjo, Joyce M van Dodewaard-de Jong, Haiko J Bloemendal, Rob Ter Heine
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer chemotherapy and pharmacology (2024)
Cilla E J Vrinzen, Linn Delfgou, Niek Waltherus Stadhouders, Rosella P M G Hermens, Matthias A W Merkx, Haiko J Bloemendal, Patrick P T Jeurissen
A systematic review and multilevel regression analysis reveals the comorbidity prevalence in cancer. Cancer research (2023)
Sahar Barjestehvan Waalwijk van Doorn-Khosrovani, Lonneke Timmers, Anke Pisters-van Roy, Joël Gijzen, Nicole M A Blijlevens, Haiko J Bloemendal
Manufacturers' views on outcome-based agreements. Journal of market access & health policy 9 (1) (2021)